Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Aliskiren/Amlodipine and Amlodipine on Ankle Foot Volume (AFV) in Patients With Hypertension

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients (male or female) with hypertension aged between 18-75 yrs.~* Patients not treated with amlodipine or no amlodipine in previous 1 year.~* Post-menopausal females~Exclusion Criteria:~* Patients unable to switch from prior hypertensive medication.~* Severe hypertension.~* Pregnant or nursing females.~* Patients with Type 1 or Type 2 diabetes mellitus~* History of immunodeficiency diseases, including a positive Human immunodeficiency virus (HIV) (Enzyme-linked immunosorbent assay \[ELISA\] and Western blot) test result.~* A positive Hepatitis B surface antigen (HBsAg) or Hepatitis C test result.~Other protocol-defined inclusion/exclusion criteria are applied

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Aliskiren/amlodipine + Placebo to amlodipine (Type: EXPERIMENTAL): During the first week of active treatment, patients were instructed to take one tablet of aliskiren/amlodipine 150/5 mg and one capsule of placebo to amlodipine daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 2 tablets of aliskiren/amlodipine 150/5 mg/day and 1 capsule of placebo to amlodipine.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day.
- Amlodipine + Placebo to aliskiren/amlodipine (Type: ACTIVE_COMPARATOR): During the first week of active treatment, patients were instructed to take one capsule of amlodipine 5 mg and one tablet of placebo to aliskiren/amlodipine 150/5 mg daily. For the 2nd to 4th week of active treatment, the patients were up-titrated to take 1 capsule of amlodipine 10 mg/day and 2 tablets of placebo to aliskiren/amlodipine 150/5 mg/day.~The patients were instructed to administer daily dose between 8:00 and 10:00 am preferably at the same time of the day.

Based on this trial design, predict the completion outcome and termination type (if applicable).